Aratana Therapeutics Inc. (PETX) Trading Down 2.8%
Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price traded down 2.8% during trading on Thursday . The company traded as low as $6.51 and last traded at $6.57, with a volume of 359,517 shares traded. The stock had previously closed at $6.76.
A number of equities analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research note on Tuesday, April 26th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Lake Street Capital reiterated a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research note on Sunday, July 17th. Credit Suisse Group AG reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Saturday, April 2nd. Finally, Jefferies Group reiterated a “buy” rating and set a $12.00 target price on shares of Aratana Therapeutics in a research note on Saturday, April 2nd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $11.66.
The firm’s market capitalization is $230.46 million. The company’s 50 day moving average price is $6.61 and its 200 day moving average price is $5.30.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities analysts anticipate that Aratana Therapeutics Inc. will post ($1.02) EPS for the current fiscal year.
In related news, insider Ernst Heinen sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $6.72, for a total transaction of $100,800.00. Following the transaction, the insider now directly owns 125,494 shares of the company’s stock, valued at $843,319.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Steven St sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $6.26, for a total transaction of $626,000.00. Following the transaction, the chief executive officer now directly owns 717,793 shares in the company, valued at $4,493,384.18. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates increased its position in shares of Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned about 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent SEC filing.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.